US FDA declines to approve higher-dose of Biogen's genetic disorder drug
23/09/2025 21:35
Sept 23 (Reuters) - The U.S. Food and Drug Administration has declined to approve a higher dose version of Biogen's BIIB.O drug for a rare genetic disorder that causes progressive muscle weakness, dealing a setback to the company's efforts to strengthen its position in a competitive market, the company said on Tuesday. (Reporting by Kamal Choudhury, Mariam Sunny and Siddhi Mahatole in Bengaluru; Editing by Krishna Chandra Eluri) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study